MS
STRO icon

Maven Securities’s Sutro Biopharma STRO Stock Holding History

Maven Securities’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,000
Closed -$3.06M – 1288
2020
Q4 		$3.06M Buy
+14,000
New +$2.32M 0.3% 78

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Maven Securities's STRO Position: Q1 2021 in Review

Maven Securities sold out of Sutro Biopharma (STRO) in Q1 2021, closing a stake of 14,000 shares — an estimated $3.06M sold.

Maven Securities first reported a position in STRO in Q4 2020 and held it in 1 quarter. The position peaked at $3.06M in Q4 2020. 138 funds tracked by Wall St. Rank hold STRO as of Q1 2021.

  • Maven Securities reported no remaining Sutro Biopharma position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 14,000 Sutro Biopharma shares in Q1 2021, an estimated $3.06M.
  • Maven Securities first reported a position in Sutro Biopharma in Q4 2020 and held it in 1 quarter.
  • Maven Securities's Sutro Biopharma position peaked at $3.06M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.